| INTRODUC TION/AIM
The introduction of extended half-life (EHL) recombinant Factor IX (rFIX) products for the treatment of haemophilia B (HB) has improved patient quality of life 1 ; however, the complexities of accurately measuring product recovery have created uncertainty within haemostasis laboratories.
Two EHL products, FIX albumin fusion protein, albutrepenona- The recommended potency assignment for replacement of FIX products is by one-stage clotting assay (OSA). 4 The potency for Alprolix was assigned by OSA using Actin APTT reagent.
5
To the best of our knowledge, the APTT reagent used for assignment of Idelvion potency is not in the public domain; however, Pathromtin SL has been used in previous clinical trials of Idelvion. where a was the FIX:C using alternative APTT reagents or CSA and b was the FIX:C using either Pathromtin SL in Idelvion samples or Actin in Alprolix samples.
| ME THODS

| RE SULTS
| Idelvion
The overall median OSA FIX:C for 18 samples from Idelvion-treated patients was 48 IU/dL with PSL, with other OSA ranging from 28 IU/dL(AFS) to 63 IU/dL (SynthAFax) and using CSA was 82 IU/ dL with Rossix and 66 IU/dL with Hyphen (see Table 1 ). At high levels, FIX:C ranged from 46 IU/dL (AFS) to 137 IU/dL (Rossix CSA) in the same sample; PSL was 78 IU/dL. At trough levels, FIX:C varied from 4 IU/dL (both CSA) to 9 IU/dL (Actin) in the same sample; PSL was 6 IU/dL. Percentage differences were calculated using PSL as the target result. For OSA, the median percentage difference ranged from −3.5% with Actin to 42.5% with SynthAFax. For CSA, the median percentage difference was 71.5% with Rossix and 41.1% with Hyphen (Table 1 and Figure 1 ).
| Alprolix
The median OSA FIX:C for 22 samples from Alprolix-treated patients ranged from 33 IU/dL with PSL to 53 IU/dL with Actin. Median CSA was 49 IU/dL with Rossix and 34 IU/dL with Hyphen (see Table 1 ). At high levels, the largest FIX:C variation in a single samples was 65 IU/ dl with APTT SP and 94 IU/dl with Actin. A single patient had a IX:C of below 10 IU/dL with Actin and the range of results was 3 IU/dl (Rossix CSA) to 8 IU/dl (Actin, APTT SP and Synthasil) in this sample.
Percentage differences were calculated using Actin as the target result. The median OSA percentage difference ranged from −22% with Synthasil to −27.4% with PSL. For CSA, the median percentage difference was −3.7%% with Rossix and −30.8% with Hyphen (Table 1 and Figure 1 ).
| DISCUSS ION/CON CLUS IONS
The laboratory monitoring of FIX products, which have been modified by fusion to albumin or the Fc portion of IgG1 molecules or by linkage of polyethylene glycol, has become a challenging issue.
The results of pharmaceutical company instigated field studies using plasma spiked with these EHL rFIX products have indicated that some commonly used APTT reagents would not be suitable for accurate measurement of these products. Field studies that used plasma artificially spiked with Alprolix concluded that the product may be measured by OSA with APTT reagents comprising ellagic acid or silica activators. The kaolin-based reagent, CK Prest, which underestimated the expected recovery by 20%-40% depending upon the FIX:C activity, would not be acceptable for monitoring. 2, 7 In HB patients treated with Alprolix, the target FIX:C was de- Currently, there is no international consensus of the degree of variation between reagents or assay methods measuring the same parameter which could be expected to alter the clinical management of patients. About 20%-30% difference has been considered acceptable in several studies. 2, 8, 9 At FIX:C below 10 IU/dL, the calculation of percentages can magnify small differences in activity which may not be clinically significant. As FIX:C trough levels can be used to tailor patient dosing regimens, it is important that these can be accurately determined; however, field studies have reported significant variability at low FIX:C concentrations. 
